Gyre Therapeutics, Inc. Total Assets
Gyre Therapeutics, Inc. (GYRE) had Total Assets of $199.25 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2026-08-07
- 2026-06-30: Assets $199.25M.
- 2026-03-31: Assets $162.01M.
- 2025-12-31: Assets $219.76M; Assets as first filed $166.13M.
- 2025-09-30: Assets $159.38M.
| Period end | Assets | Assets as first filed |
|---|---|---|
| 2026-06-30 | $199.25M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $162.01M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $219.76M 10-Q · filed 2026-08-07 | $166.13M 10-K · filed 2026-03-13 |
| 2025-09-30 | $159.38M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $152.65M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $129.79M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $125.41M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $125.24M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $120.93M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $122.01M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $116.54M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $9.96M 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $12.39M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $18.75M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $84.75M 10-K · filed 2024-03-27 | $28.44M 10-K · filed 2023-03-30 |
| 2022-09-30 | $31.02M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $83.37M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $40.27M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $55.66M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $78.54M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $101.79M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $119.08M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $94.85M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $111.80M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $123.68M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $110.56M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $98.55M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $91.79M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $100.87M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $111.87M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $124.92M 10-K · filed 2020-02-20 | |
| 2018-09-30 | $133.42M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $139.54M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $145.89M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $39.51M 10-K · filed 2019-03-08 | |
| 2017-09-30 | $34.39M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $39.63M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $29.06M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $38.09M 10-K · filed 2018-03-19 | |
| 2016-09-30 | $51.62M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $57.22M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $61.54M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $69.52M 10-K · filed 2017-03-08 | |
| 2015-09-30 | $74.51M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $3.33M 8-K/A · filed 2015-10-23 | $101.17M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $107.14M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $2.98M 10-K · filed 2016-03-09 | $112.00M 10-K · filed 2015-03-16 |
| 2014-09-30 | $116.12M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $124.52M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $134.11M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $5.27M 8-K/A · filed 2015-10-23 | $145.87M 10-K · filed 2014-03-14 |
| 2013-09-30 | $157.85M 10-Q · filed 2013-11-06 | |
| 2013-06-30 | $167.49M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $178.75M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $189.58M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $203.50M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $212.62M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $231.10M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $258.13M 10-K · filed 2013-03-15 | |
| 2011-09-30 | $279.74M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $300.02M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $262.79M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |